MGMT and central nervous system cancer: To intuitively predict the prognosis of glioma patients, we constructed a nomogram (Fig. 4A) using RS and clinicopathological variables (age, gender, WHO grade, IDH mutation, 1p19q codeletion, MGMT promoter methylation) and provided a web version (https://dnszy.shinyapps.io/Glioma_OS_lncRNA/) to facilitate the assessment of patient prognosis by clinicians (Fig. 4B).